Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....
W. Quan, D. Henault, S. M. Hasnain et al.· Cancer Research· 0 citations
Malignant cells do not exist in isolation. In pancreatic ductal adenocarcinoma (PDAC), malignant cells reside within distinct spatial niches shaped by stromal, immune, endothelial, and neural compartments, and this spatial context is linked to therapeutic resistance and clinical outcome. While genomic alterations dri...
Sibyl Drissler, Noor Shakfa, Elizabeth Sunnucks et al.· Cancer Research· 0 citations
The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.
Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al.· Cancer Research· 0 citations
This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.
J. Romero, Yi-Fan Wang, Edward Shanbedi et al.· Cancer Research· 0 citations
A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the priorit...
Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.